Vol.

No.

June 18, 2026Jun 18, 2026

DOWNLOAD THE PDF

Is psilocybin heading to a cancer clinic near you? Reversing Nixon-era taboo, Trump orders FDA to fast-track psychedelics and ARPA-H to fund research

Cover Story

Regulatory News

Is psilocybin heading to a cancer clinic near you?

Reversing Nixon-era taboo, Trump orders FDA to fast-track psychedelics and ARPA-H to fund research

By Sara Willa Ernst

Earlier this year, Joe Rogan, host of “The Joe Rogan Experience” podcast, sent a text to President Donald Trump.

Clinical Trials & Tribulations

What NHS-Galleri taught us—and what it didn’t

By Scott D. Ramsey and Ruth Etzioni

Clinical Trials & Tribulations

The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies

By Bryan Bassig, Catherine R. Marinac, David M. Routman, Elizabeth K. O'Donnell, Jennifer Keating Litton, Karthik V. Giridhar, Kennedy Ng Yao Yi, Kurt Giles, Nima Nabavizadeh, Ora K. Gordon, Rebecca Kaltman and Shawn Kothari

News Analysis

FDA clears a way for dramatic reduction in animal toxicology studies in cancer

By Claire Marie Porter

Cancer Policy

OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds

Early-onset cancer bill introduced in Congress

In Brief

Ian Krop named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs at Yale

Veena Shankaran receives the Lert Family Endowed Chair at Fred Hutch

NCI renews the UC San Diego Moores CCSG, committing $25M

UCLA researchers awarded $3.2M NIH grant to improve detection and treatment of glioblastoma

Kara Marshall receives the 2026 McKnight Scholar Award

St. Jude Graduate School earns accreditation from Southern Association of Colleges and Schools Commission on Colleges

Clinical Roundup

All-oral regimen of decitabine-cedazuridine + venetoclax yields 47% complete response rate, ASCERTAIN-V phase I/II clinical trial finds

Talvey + Darzalez Faspro shows significant survival gains in r/r MM, phase III MonumenTAL-3 study finds

Jaypirca + venetolax + rituximab reduced the risk of disease progression or death by 45% in r/r CLL/SLL, phase III BRUIN CLL-322 trial finds

Vispa-cel well-tolerated in second-line large B cell lymphoma, ANTLER phase I study finds

Antibody may improve treatment response in lung cancer, UTSW-led study finds

Alliance digital tool proves effective at keeping patients engaged in trials

Pediatric cancer exercise guidelines recommend movement during and after treatment

Drugs & Targets

FDA approves Ambelvist for contrast-enhanced MRI to detect and visualize lesions with abnormal vascularity

FDA accepts sBLA for atezolizumab for patients with stage 3 dMMR colon cancer

FDA warns providers about shortage of breast biopsy needles

PREVIOUS ISSUE

NEXT ISSUE

Recent Issues

Is psilocybin heading to a cancer clinic near you?

What NHS-Galleri taught us—and what it didn’t

The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies

FDA clears a way for dramatic reduction in animal toxicology studies in cancer

Cancer Policy

OMB proposed rule could end 50% of currently active clinical trials, Stand up for Science analysis finds

Early-onset cancer bill introduced in Congress

In Brief

Ian Krop named section chief of Medical Oncology and Hematology and deputy director for Clinical Affairs at Yale

Veena Shankaran receives the Lert Family Endowed Chair at Fred Hutch

NCI renews the UC San Diego Moores CCSG, committing $25M

UCLA researchers awarded $3.2M NIH grant to improve detection and treatment of glioblastoma

Kara Marshall receives the 2026 McKnight Scholar Award

St. Jude Graduate School earns accreditation from Southern Association of Colleges and Schools Commission on Colleges

Clinical Roundup

All-oral regimen of decitabine-cedazuridine + venetoclax yields 47% complete response rate, ASCERTAIN-V phase I/II clinical trial finds

Talvey + Darzalez Faspro shows significant survival gains in r/r MM, phase III MonumenTAL-3 study finds

Jaypirca + venetolax + rituximab reduced the risk of disease progression or death by 45% in r/r CLL/SLL, phase III BRUIN CLL-322 trial finds

Vispa-cel well-tolerated in second-line large B cell lymphoma, ANTLER phase I study finds

Antibody may improve treatment response in lung cancer, UTSW-led study finds

Alliance digital tool proves effective at keeping patients engaged in trials

Pediatric cancer exercise guidelines recommend movement during and after treatment

Drugs & Targets

FDA approves Ambelvist for contrast-enhanced MRI to detect and visualize lesions with abnormal vascularity

FDA accepts sBLA for atezolizumab for patients with stage 3 dMMR colon cancer

FDA warns providers about shortage of breast biopsy needles

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login